CHC Healthcare Group (4164) Fair Value & Analysis
Healthcare · TW · Market cap 5.2B TWD
Fair value as of: Jul 23, 2026
From 25 valuation models · updated 18 days ago
Share price −8.1% over the past month.
Below-average quality, and screening another 37% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (21.10 TWD). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (10.41 TWD to 21.10 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 25.90 TWD – 71.65 TWD · fair‑value band 10.41 TWD – 21.10 TWD · the 26.65 TWD price screens above the 16.81 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
CHC Healthcare Group (4164) currently trades at 26.65 TWD, while our model-based Fair Value estimate is 16.81 TWD, implying the stock looks roughly 36.9% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, CHC Healthcare Group generated revenue of 4.6B TWD at a net margin of 4.5%. Revenue grew 15.2% year over year. It earns a return on equity of 3.4%. Net debt stands at 3.6B TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 10.41 TWD (bear case) to 21.10 TWD (bull case); at 26.65 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -37%, 4164 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Asset-Based (26.38 TWD) versus Economic Profit (8.85 TWD). Highest evidence: Growth DCF (80).
Notify me when 4164 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
CHC Healthcare Group, together with its subsidiaries, trades in medical equipment, pharmaceutical products, and health food in Taiwan, China, and internationally.
Full company description
CHC Healthcare Group, together with its subsidiaries, trades in medical equipment, pharmaceutical products, and health food in Taiwan, China, and internationally. The company is also involved in the leasing, installing, servicing, and repairing of medical instruments for use in various specialties, such as radiation oncology, medical imaging, neurology, surgery, ophthalmology, robot rehabilitation, dentistry, and smart health care. In addition, it engages in the irradiation business; sale of daily necessities, beauty products, and health supplements; elderly residence, long-term care, and senior services; leasing of veterinary medical instruments; department setup, business management consultation, and educational training and staff development for healthcare personnel; technical support and maintenance; radiation sterilization business; and online and physical store pharmacy chain activities. The company was formerly known as Cheng Yeh Holdings Co., Ltd. and changed its name to CHC Healthcare Group in 2012. CHC Healthcare Group was incorporated in 2009 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CHC Healthcare Group reported revenue of 4.4B TWD in FY2025 versus 2.4B TWD in FY2021, a compound +15.9%/yr. Reported net income was 186M TWD in FY2025, compounding −16.4%/yr from FY2021.
of which total revenue +6.6 pp · buybacks/dilution −4.4 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
4164 screens 37% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare CHC Healthcare Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CHC Healthcare Group (4164) overvalued or undervalued?
What is the fair value of 4164?
What is the quality score of 4164?
What is the revenue of CHC Healthcare Group (4164)?
What is the net profit margin of 4164?
Does CHC Healthcare Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track CHC Healthcare Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.